Showing results (371-380 of 537) with videos related to

Sort By:
Pageof 54
Brain Communications|March 6, 2024
Unraveling the directional relationship of sleep and migraine-like painRobson C Lillo Vizin, Caroline M Kopruszinski, Paula M Redman, et al.
Headache|February 6, 2021
Real-world efficacy, tolerability, and safety of ubrogepantChia-Chun Chiang, Karissa N Arca, Rachel B Dunn, et al.
Clinical Journal of Sport Medicine : Official Journal of the Canadian Academy of Sport Medicine|January 13, 2017
Concussion in Ice Hockey: Current Gaps and Future Directions in an Objective DiagnosisAynsley M Smith, Michael J Stuart, William O Roberts, et al.
Mayo Clinic Proceedings|May 2, 2016
Impact of Migraine on the Family: Perspectives of People With Migraine and Their Spouse/Domestic Partner in the CaMEO StudyDawn C Buse, Ann I Scher, David W Dodick, et al.
Headache|December 15, 2019
Most Bothersome Symptom in Persons With Migraine: Results From the Migraine in America Symptoms and Treatment (MAST) StudySagar Munjal, Preeti Singh, Michael L Reed, et al.
Headache|May 20, 2022
The impact of pre-morbid headaches on headache features and long-term health outcomes following traumatic brain injury: Insights from the American Registry for Migraine ResearchZachary Leibovit-Reiben, Ryotaro Ishii, David W Dodick, et al.
The Neurologist|September 13, 2007
Caffeine for the prevention and treatment of postdural puncture headache: debunking the mythRashmi B Halker, Bart M Demaerschalk, Kay E Wellik, et al.
Mayo Clinic Proceedings|October 4, 2011
MAP0004, orally inhaled dihydroergotamine for acute treatment of migraine: efficacy of early and late treatmentsStewart J Tepper, Shashidhar H Kori, Peter J Goadsby, et al.
Cephalalgia : an International Journal of Headache|April 1, 2020
Comparison of healthcare resource utilization and costs among patients with migraine with potentially adequate and insufficient triptan responseSteven C Marcus, Anand R Shewale, Stephen D Silberstein, et al.
Cephalalgia : an International Journal of Headache|June 9, 2016
A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraineTiffini Voss, Richard B Lipton, David W Dodick, et al.
Pageof 54